Terpolymer-Coated Filter for Prion and Leukocyte Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for removing abnormal prion proteins from blood products are inefficient and often require separate processes for leukocyte removal, leading to increased costs, labor, and potential activation of the clotting system, making them unsuitable for simultaneous removal with leukocytes.
Innovation Solution
A filter coated with a terpolymer comprising 20-40 mol% hydrophobic polymerizable monomer, 5-13 mol% polymerizable monomer with a basic nitrogen-containing part, and a protonic neutral hydrophilic part is used to efficiently remove abnormal prion proteins and leukocytes from blood products, with radiation and autoclave sterilization enhancing the filtration process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional filtration methods are used to remove abnormal prion proteins, then removal efficiency is low, but the process complexity and cost increase due to requiring separate leukocyte removal steps
Solution Approach 1:
The patent combines leukocyte removal and abnormal prion protein removal into a single filtration process using a filter with a specific porous structure. The filter simultaneously removes both leukocytes and abnormal prion proteins in one operation, eliminating the need for separate filtration steps and reducing process complexity while improving overall removal efficiency.
Solution Approach 2:
The filter is designed with a specific porous structure that provides multi-functionality: it removes leukocytes, removes abnormal prion proteins, and maintains blood product quality. This universal filter design performs multiple removal functions that previously required separate specialized filters or processes.
2Reliability
If separate filtration processes are used for leukocyte and prion protein removal, then removal capability is improved, but labor and cost increase
Solution Approach 1:
The patent merges leukocyte removal and abnormal prion protein removal into a single filtration operation. The filter's specific porous structure enables simultaneous removal of both targets in one pass through the filter, reducing processing time and labor requirements while maintaining high removal capability for both leukocytes and prion proteins.
3Reliability
If conventional filters are used, then leukocyte removal is effective, but abnormal prion protein removal is insufficient and additional processing is needed
Solution Approach 1:
The filter is designed with a specific porous structure that provides universal removal capability for both leukocytes and abnormal prion proteins. This multi-functional filter eliminates the need for separate manufacturing processes for different filtration stages, simplifying manufacturing while ensuring effective removal of both targets.
4Ease of manufacture
If radiation sterilization is used, then cost is reduced, but preservative solution and anticoagulant decompose
Solution Approach 1:
The patent applies preliminary action by performing filtration and removal of abnormal prion proteins and leukocytes before sterilization. This sequence allows radiation sterilization to be applied to the filtered blood product without compromising the integrity of preservative solutions and anticoagulants, as the sensitive components have already been removed or protected during the filtration process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the easy and efficient removal of abnormal prion proteins and leukocytes, producing high-quality blood products with low hemolysis and improved flowability, while maintaining the quality and safety of the filtration process.
Implementation Method 1
A filter coated with a terpolymer comprising 20-40 mol% hydrophobic polymerizable monomer, 5-13 mol% polymerizable monomer with a basic nitrogen-containing part, and a protonic neutral hydrophilic part is used to efficiently remove abnormal prion proteins and leukocytes from blood products
Implementation Method 2
radiation and autoclave sterilization enhancing the filtration process
Implementation Method 3
radiation and autoclave sterilization enhancing the filtration process
Implementation Method 4
A filter coated with a terpolymer comprising 20-40 mol% hydrophobic polymerizable monomer, 5-13 mol% polymerizable monomer with a basic nitrogen-containing part, and a protonic neutral hydrophilic part is used to efficiently remove abnormal prion proteins and leukocytes from blood products
Data Source
AI summary
Provided are a method of conveniently and efficiently removing abnormal prion protein from a blood product and a method of removing leukocyte simultaneously with abnormal prion protein. The method of removing an abnormal prion protein from a blood product includes filtering the blood product through a filter filled with a carrier coated with a polymer, which is composed of three units including 20 mol % or more and 40 mol % or less of a unit originating from a hydrophobic polymerizable monomer, 5 mol % or more and 13 mol % or less of a unit originating from a polymerizable monomer containing a basic nitrogen-containing part, and a unit originating from a polymerizable monomer containing a protonic neutral hydrophilic part as the balance, and then recovering the filtered blood product.